Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate

Kereiakes, Dean J.; Neutel, Joel M.; Punzi, Henry; Xu, Jianbo; Lipka, Leslie J.; Dubiel, Robert

doi:10.2165/00129784-200707050-00006

Cited by 32 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,16,[34][35][36][37][38][39][40][41][42][43] Numerous studies have reported the incidence of peripheral edema in patients receiving combined treatment with a CCB and a RAAS inhibitor versus an alternate regimen (Table 3). 12,[15][16][17][35][36][37][38][39][40][41][42][43][44][45][46][47][48] The combination of a CCB and RAAS blocker has been shown in many studies to be associated with a lower rate of peripheral edema than monotherapy with the same dose of CCB (Table 3). Amlodipine besylate is the most frequently prescribed CCB in clinical practice.…”

Section: Calcium Channel Blocker-induced Lower Extremity Edemamentioning

confidence: 99%

Managing Peripheral Edema in Patients With Arterial Hypertension

Epstein¹,

Roberts²

2009

American Journal of Therapeutics

View full text Add to dashboard Cite

Calcium channel blockers (CCBs) play a vital role in the management of hypertension. Peripheral edema is the most common side effect reported with CCB monotherapy, especially with high-dose dihydropyridine CCBs. CCB-related peripheral edema is a dose-limiting effect that is usually medically benign but can compromise patient adherence. CCB-related peripheral edema may cause considerable discomfort and patient concern. Patients presenting with peripheral edema should undergo assessment for drug and nondrug causes. Rather than lowering the CCB dose or switching to another monotherapy, combination therapy (e.g, CCB plus a renin-angiotensin-aldosterone system inhibitor) can enhance blood pressure control, generally with lower doses of individual agents, and lessen the risk of adverse events. As recommended by consensus guidelines, addition of a renin-angiotensin-aldosterone system inhibitor as part of combination therapy may accelerate the time to goal blood pressure as well as help alleviate peripheral edema in affected patients. Successful management of CCB-related peripheral edema with lifestyle changes and rational combination therapy is likely to improve blood pressure control and patient outcomes.

show abstract

Section: Calcium Channel Blocker-induced Lower Extremity Edemamentioning

confidence: 99%

Managing Peripheral Edema in Patients With Arterial Hypertension

Epstein¹,

Roberts²

2009

American Journal of Therapeutics

View full text Add to dashboard Cite

show abstract

“…4,5 The renin system is a key target for antihypertensive therapy, and combination therapy involving either angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) has proved effective in lowering BP in patients with stage 2 hypertension. [6][7][8][9] The oral direct renin inhibitor (DRI) aliskiren, which acts at the point of activation of the renin system by reducing plasma renin activity, provides an effective treatment option for this patient group. 10 Aliskiren has demonstrated effective BP lowering and a good safety and tolerability profile, both as monotherapy and in combination with other antihypertensive agents, in clinical trials in patients with mild to moderate hypertension.…”

Section: Introductionmentioning

confidence: 99%

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

Yarows

Oparil²,

Patel

et al. 2008

Adv Therapy

View full text Add to dashboard Cite

show abstract

“…In the most important of the comparative studies against monotherapy, olmesartan/ hydrochlorothiazide combinations were more successful than their respective monotherapies [28]. Furthermore, in comparative studies against other combinations, olmesartan/hydrochlorothiazide reduced SBP significantly more than combinations of amlodipine and benazepril [29] or of losartan and hydrochlorothiazide [30].…”

Section: Olmesartan In Combination Therapymentioning

confidence: 98%

Olmesartan-based therapies

Sierra

Volpe

2013

Journal of Hypertension

View full text Add to dashboard Cite

The main purpose in hypertension treatment is the reduction of cardiovascular disease burden. Among different first-line antihypertensive drug classes, angiotensin-receptor blockers are characterized by their both good effectiveness and tolerability. Furthermore, the interruption of the renin-angiotensin cascade is related with several benefits in target organ protection and cardiovascular prevention. Among different angiotensin-receptor blockers, olmesartan has been examined in several trial of organ protection, showing improvements in several disease markers, such as microinflammation, regression of both plaque volume and vascular hypertrophy, as well as microalbuminuria prevention. Olmesartan has been also widely examined in combination of either hydrochlorothiazide or amlodipine, as well as with both drugs in a single-pill triple combination, showing improvements in antihypertensive efficacy without significant effects on tolerability. This treatment strategy based on a drug with such characteristics and the availability of different types of combinations with other first-line drug classes may represent an effective way for achieving blood pressure control in a majority of hypertensive patients and this could also be related with a better cardiovascular disease prevention.

show abstract

Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate

Abstract: Olmesartan medoxomil/HCTZ 40/12.5 and 40/25 mg/day combination therapy was well tolerated and demonstrated a greater antihypertensive effect than benazepril plus amlodipine besylate 20/5 and 20/10 mg/day and this enabled more patients to achieve targeted BP goals.

Cited by 32 publications

References 28 publications

Managing Peripheral Edema in Patients With Arterial Hypertension

Managing Peripheral Edema in Patients With Arterial Hypertension

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

Olmesartan-based therapies

Contact Info

Product

Resources

About